<- Go Home
GRAIL, Inc.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Market Cap
$1.8B
Volume
1.3M
Cash and Equivalents
$853.6M
EBITDA
-$631.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$80.7M
Profit Margin
68.59%
52 Week High
$63.99
52 Week Low
$12.33
Dividend
N/A
Price / Book Value
0.67
Price / Earnings
-0.82
Price / Tangible Book Value
3.26
Enterprise Value
$986.0M
Enterprise Value / EBITDA
-1.64
Operating Income
-$789.5M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$853.6M
Debt
$72.2M
Equity
$2.6B
Revenue
$117.7M
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium